ReviewCurrent hematologic malignancy reports2018
Management of Myelofibrosis-Related Cytopenias.
Review in Current hematologic malignancy reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.Advances in therapy · 2024Trial
- Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.American journal of hematology · 2022Trial
- Emerging Therapeutic Approaches for Anemia in Myelofibrosis.Current hematologic malignancy reports · 2025Review
- Reconstructing skeletal homeostasis through allogeneic hematopoietic stem cell transplantation in myelofibrosis.Nature communications · 2025Article
- Review
- Article
- Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.Clinical and translational science · 2024Article
- Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.Future oncology (London, England) · 2024Article
- Roles of MMP-2 and MMP-9 and their associated molecules in the pathogenesis of keloids: a comprehensive review.Frontiers in pharmacology · 2024Review
- Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins.Blood science (Baltimore, Md.) · 2023Article
- Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.EJHaem · 2023Review
- Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.Cancers · 2023Review
- SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.Clinical lymphoma, myeloma & leukemia · 2023Review
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia.Journal of hematology & oncology · 2022Review
- Management of myelofibrosis after ruxolitinib failure.Leukemia & lymphoma · 2020Article
- Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to.Annals of hematology · 2020Review
- Management of Myelofibrosis: from Diagnosis to New Target Therapies.Current treatment options in oncology · 2020Review
- Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.Leukemia · 2019Review
- New Concepts of Treatment for Patients with Myelofibrosis.Current treatment options in oncology · 2019Review
- Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.Expert opinion on orphan drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewCytopenias, particularly anemia, are frequently encountered in patients with myelofibrosis. Management of cytopenias in myelofibrosis can be very challenging because current therapeutic interventions are only of modest efficacy and ruxolitinib, the only approved drug for myelofibrosis, is myelosuppressive. Yet, dose optimization of ruxolitinib is important for its survival benefit in patients with advanced disease. We sought to summarize the data on treatments for cytopenias available at present and review promising agents in development and emerging strategies. RECENT
findingsThe activin receptor ligand traps hold considerable promise for the treatment of anemia and could represent an attractive combination strategy with ruxolitinib. Low-dose thalidomide, which could offset both anemia and thrombocytopenia caused by ruxolitinib, represents another potential partner for ruxolitinib. The anti-fibrotic agent PRM-151 produced sustained improvements in cytopenias in some patients, and further data on this drug are eagerly awaited. Finally, several preclinical leads with translational potential are worthy of clinical investigation as strategies to halt/reverse bone marrow fibrosis and thereby improve cytopenias. Cytopenias remain a significant hurdle in myelofibrosis management, but several novel investigational agents hold considerable promise for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.